Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erectile Dysfunction Class Labeling Does Not Assert Causal Link To Vision Loss

This article was originally published in The Pink Sheet Daily

Executive Summary

Labeling revisions for Viagra, Levitra and Cialis will add information about NAION adverse events, but states that “it is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors.”

You may also be interested in...



FDA Endpoint Development For Pediatric Pulmonary Arterial Hypertension Focuses On Pfizer's Revatio

The standard exercise test is a problem for many pediatric patients, and FDA's Cardiovascular and Renal Drugs Advisory Committee will assess alternatives.

FDA Endpoint Development For Pediatric Pulmonary Arterial Hypertension Focuses On Pfizer's Revatio

The standard exercise test is a problem for many pediatric patients, and FDA's Cardiovascular and Renal Drugs Advisory Committee will assess alternatives.

ED Drug Labeling Revised For Potential Risk Of Hearing Loss

FDA identifies 29 postmarketing reports of sudden hearing loss in patients using PDE 5 inhibitors, including Cialis, Levitra and Viagra.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel